Routes To Sponsor Of Choice: From Shared Pipelines To Streamlined Payments

Increasingly, sponsors are competing for clinical trial sites and want to distinguish themselves from their peers to become sites’ first choice for partnerships. To this end, companies are creating “sponsor-of-choice” initiatives that look for ways to improve site-sponsor relationships. Investing in a clinical trial payment solution that ensures sites get paid reliably and efficiently is one of the most important ways to be a sponsor of choice.

Clinical Leader and IQVIA Technologies recently explored this issue in Trends in Sponsor-of-Choice Initiatives: Consolidating Site Payments in a Multiple CRO Model with George Kourtsounis, Senior Director for Clinical Trial Contracts and Grants at Bristol Myers Squibb; Casey Orvin, Chief Commercial Officer at CenExel Centers of Excellence; and Jim DiCesare, Senior Director of Study Operations for IQVIA Clinical Trial Payments, a third-party site payments provider that operates independently of IQVIA’s contract research organization (CRO).

The panel agreed that paying clinical trial sites on time, every time, provides stability in difficult times and maintains positive relationships between sponsors and sites. Companies like BMS that are working to become a sponsor of choice avoid the trap of relying on the study’s CRO for payments processing by adopting a singular clinical trial payment solution across their studies.